FDA Leadership Shakeup Sparks Gene Therapy Market Fluctuations
TL;DR Summary
Nicole Verdun, a key regulator of gene therapies at the FDA, and her deputy Rachael Anatol have been placed on administrative leave and escorted out of the agency, amid ongoing changes in the regulation of gene therapies and the departure of former FDA leadership.
- Top gene therapy regulator forced out at FDA STAT
- FDA’s gene therapy turmoil, and an alternative model for funding research STAT
- Industry disappointed as FDA puts gene therapy chief on leave Fierce Biotech
- US FDA’s Top Cell and Gene Therapy Regulators Forced Out insights.citeline.com
- Gene editing stocks gain amid FDA's latest leadership change (EDIT:NASDAQ) Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
81%
231 → 44 words
Want the full story? Read the original article
Read on STAT